SGLT2 inhibitors contributed to a significant risk reduction for all-cause mortality (RR 0.92, 95% CI 0.85–0.99, P = .04, I2 = 0%) and CV death (RR 0.91, 95% CI 0.83–0.99, P = .01, I2 = 25.1%) in patients with HF, but insignificant in those without HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.